First Oral Small-Molecule GLP-1 Drug Orforglipron (Foundayo™) Approved – A New Era in Obesity Treatment

Since GLP-1 therapies revolutionized the treatment of metabolic diseases, the "Holy Grail" of drug development has been clear: transforming injectable medications into convenient oral pills. That vision has now become a reality.

On April 1, 2026, Eli Lilly and Company announced that the U.S. FDA has approved Orforglipron (trade name: Foundayo™) for the treatment of obesity and overweight adults. As the world's first approved oral small-molecule, non-peptide GLP-1 receptor agonist, this milestone marks the official start of a new, convenient era in weight management.

A Disruptive Technological Approach

Unlike familiar drugs such as semaglutide or tirzepatide, Orforglipron is not a peptide analog. It is a small-molecule drug with a novel chemical structure.

This differentiation offers a significant practical advantage: it can be taken without food or water restrictions. Patients no longer need to fast for 30 minutes before taking the medication, as required with oral semaglutide. Orforglipron can be taken at any time of day, greatly simplifying the treatment routine.

Robust Clinical Evidence: Weight Loss and Cardiometabolic Benefits

The approval is based on the Phase 3 ATTAIN clinical program. Data show that Orforglipron delivers excellent weight loss results, particularly at the highest dose.

• In the ATTAIN-1 study involving non-diabetic patients with obesity, participants receiving the 36 mg dose achieved an average weight loss of 11.2% after 72 weeks. Moreover, over half (54.6%) of these participants experienced weight loss exceeding 10%.
• In the ATTAIN-2 study involving patients with obesity and type 2 diabetes, the 36 mg dose led to an average weight loss of 10.5% , along with a clinically meaningful reduction in HbA1c levels. Among these patients, 75% achieved HbA1c levels below the diagnostic threshold for diabetes.

Beyond weight loss and blood sugar control, Orforglipron has demonstrated cardiovascular benefits. Compared to placebo, the study showed significant improvements in waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol. An analysis of Phase 2 data further confirmed that the drug significantly reduces key cardiovascular risk biomarkers, including LDL, apolipoprotein B (ApoB), and high-sensitivity C-reactive protein (hsCRP).

From "Step-Up" to "Maintenance": Solving the Adherence Problem

Results from the ATTAIN-MAINTAIN study, published in Nature Medicine in May 2026, provide even more strategic evidence for Orforglipron. This study evaluated the effect of switching from injectable drugs (such as tirzepatide or semaglutide) to oral Orforglipron.

The results showed that Orforglipron successfully helped patients maintain the weight loss they had achieved. Among participants who had reached a weight loss plateau using tirzepatide, those who switched to Orforglipron maintained 74.7% of their initial weight loss over 52 weeks. In contrast, the placebo group maintained only 49.2% of their initial loss.

"Obesity is a chronic disease requiring long-term management," the researchers noted. Orforglipron provides a convenient oral option to prevent weight regain after initial weight loss success.

Safety Overview

Regarding safety, the overall profile of Orforglipron is consistent with known GLP-1 class medications. The most common adverse events were gastrointestinal (e.g., nausea, diarrhea), mostly mild to moderate. A subgroup analysis of patients aged 65 and older showed that the safety profile was consistent with the general population, suggesting that age should not be a barrier to use.

Global Outlook

Eli Lilly has now submitted approval applications to more than 40 countries worldwide, including China. With the arrival of Orforglipron, GLP-1 drugs are being liberated from the burden of injections, moving toward a more accessible and widely adoptable public health tool.

Remark: This content is AI-generated and for reference only. It is compiled from online sources. Please refer to official information for accuracy.

Syntame Exhibition Tour 2025